Edition:
United Kingdom

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

37.69USD
9:00pm BST
Change (% chg)

$-0.12 (-0.32%)
Prev Close
$37.81
Open
$37.81
Day's High
$38.28
Day's Low
$37.26
Volume
753,758
Avg. Vol
551,174
52-wk High
$129.47
52-wk Low
$25.62

Latest Key Developments (Source: Significant Developments)

Tesaro Q2 Loss Per Share $3.04
Thursday, 2 Aug 2018 

TESARO Inc ::TESARO ANNOUNCES SECOND-QUARTER 2018 OPERATING RESULTS.Q2 LOSS PER SHARE $3.04.Q2 REVENUE $54 MILLION VERSUS I/B/E/S VIEW $63.3 MILLION.Q2 EARNINGS PER SHARE VIEW $-2.65 -- THOMSON REUTERS I/B/E/S.DATA EXPECTED FROM TSR-042 (ANTI-PD-1) GARNET NSCLC AND MSI-HIGH ENDOMETRIAL EXPANSION COHORTS IN 2H 2018.SEES 2018 TOTAL NET, WORLDWIDE REVENUE OF $250 MILLION TO $265 MILLION.REVISING ITS 2018 FINANCIAL GUIDANCE TO REFLECT DIVESTITURE OF VARUBI IN U.S. AND CANADA.FY2018 REVENUE VIEW $302.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer
Monday, 26 Mar 2018 

March 26 (Reuters) - Tesaro Inc ::DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER.TESARO INC - ‍EFFICACY OF NIRAPARIB IN COMBINATION WITH AN ANTI-PD-1 MAB SURPASSES HISTORICAL EFFICACY BENCHMARKS FOR PD-1 OR PARP MONOTHERAPIES​.TESARO INC - COMBINATION OF NIRAPARIB WITH PEMBROLIZUMAB WAS WELL TOLERATED WITH AN INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA OF 9%.TESARO-POTENTIAL APPROACH TO REDUCE INCIDENCE OF GRADE 3 OR 4 THROMBOCYTOPENIA IDENTIFIED BASED ON RETROSPECTIVE ANALYSIS OF DATA FROM PHASE 3 NOVA TRIAL.TESARO - IN ADDITION TO THROMBOCYTOPENIA, OTHER MOST COMMONLY OBSERVED GRADE ≥3 ADVERSE EVENTS N STUDY INCLUDED ANEMIA AND NEUTROPENIA.  Full Article

Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION.TESARO INC - CHANGES TO LABELING INCLUDE MODIFICATIONS TO CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, AND ADVERSE REACTIONS SECTIONS.TESARO - ANAPHYLAXIS, ANAPHYLACTIC SHOCK HAVE BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING, SOME REQUIRING HOSPITALIZATION.TESARO - OTHER "SERIOUS" HYPERSENSITIVITY REACTIONS HAVE ALSO BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING.TESARO - MOST REACTIONS HAVE OCCURRED DURING OR SOON AFTER INFUSION OF VARUBI INJECTABLE EMULSION AND WITHIN FIRST FEW MINUTES OF ADMINISTRATION.  Full Article

Tesaro secures $500 million non-dilutive term loan financing
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Tesaro Inc :Tesaro secures $500 million non-dilutive term loan financing.Loans will mature in December 2024​.Loan facility provides Tesaro with up to $500 million of borrowing capacity available in two tranches​.Plan to use proceeds to strengthen PARP inhibitor franchise in ovarian cancer, expand development of Zejula in other tumor types​.  Full Article

Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Tesaro Inc :Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer.Tesaro Inc - ‍approval supported by "robust" data from a randomized phase 3 trial​.Tesaro Inc - ‍Tesaro plans to launch Zejula in Germany and UK this December, with launches in additional European countries to follow beginning in 2018​.  Full Article

Tesaro reports Q3 loss per share $0.47
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Tesaro Inc ::Tesaro announces third-quarter 2017 operating results.Q3 loss per share $0.47.Q3 revenue $142.8 million versus I/B/E/S view $132.8 million.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Tesaro Inc - ‍positive CHMP opinion issued for zejula in e.u. & commercial launch anticipated to begin by year-end​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

Photo

AstraZeneca, Merck eye $1 billion boost from cancer drug success

LONDON AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.